(R)-Oxiracetam - CAS 68252-28-8
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
(R)-Oxiracetam
Catalog Number:
68252-28-8
Synonyms:
(R)-(+)-Oxiracetam
CAS Number:
68252-28-8
Description:
(R)-Oxiracetam is the (R)-enantiomer of the nootropic drug oxiracetam, which is a nootropic drug of the racetam family and stimulant. It is safe even when high doses are consumed for a long period of time, but it is not approved by Food and Drug Administration for any medical use in the United States.
Molecular Weight:
158.16
Molecular Formula:
C6H10N2O3
COA:
Inquire
MSDS:
Inquire
Targets:
Others
Chemical Structure
CAS 68252-28-8 (R)-Oxiracetam

Related Products


NSC-601980 analog
(CAS: 91757-46-9)

NSC-601980 analog is the analog of the NSC601980, which shows antitumor activity in the yeast screening experiment.

CAS 51-05-8 Procaine hydrochloride

Procaine hydrochloride
(CAS: 51-05-8)

Procaine hydrochloride is a local anesthetic drug of the amino ester group. It is used primarily to reduce the pain of intramuscular injection of penicillin, an...

CAS 529-59-9 Genistin

Genistin
(CAS: 529-59-9)

Genistinis, a derivative of Genistein, is selective inhibitor of mammalian terminal deoxynucleotidyl transferase.

CAS 300586-90-7 OAC1

OAC1
(CAS: 300586-90-7)

OAC1 is a Octamer-binding transcription factor 4 (Oct4)-activating compound; enhances the iPSC reprogramming efficiency and accelerated the reprogramming proces...

CAS 441785-25-7 Besifovir

Besifovir
(CAS: 441785-25-7)

Besifovir is an orally available phosphonate nucleotide for the potential treatment of hepatitis B virus infection was well tolerated and also had a good clinic...

CAS 15421-84-8 Trapidil

Trapidil
(CAS: 15421-84-8)

Trapidil, also called as Rocornal, is a platelet aggregation inhibitor with specific platelet-derived growth factor.

BVT 2733
(CAS: 376640-41-4)

BVT 2733 is a non-steroidal small molecule as a a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor (IC = 96 ± 14 nM w).

CAS 480-10-4 Astragalin

Astragalin
(CAS: 480-10-4)

Astragalin is a flavonoid with anti-inflammatory activity and newly found in persimmon leaves and green tea seeds.

Cgp 13143
(CAS: 75919-69-6)

Cgp 13143 is a bio-active chemical,but no detailed information has been published yet.

CAS 73870-35-6 Foresaconitine

Foresaconitine
(CAS: 73870-35-6)

Foresaconitine is a norditerpenoid alkaloid isolated from the processed tubers of Aconitum carmichaeli.

CAS 216167-95-2 Elsibucol

Elsibucol
(CAS: 216167-95-2)

Elsibucol, a metabolically stable derivative of probucol, inhibits atherosclerosis and preserves endothelial healing following arterial injury. In vitro, elsibu...

CAS 528-43-8 Magnolol

Magnolol
(CAS: 528-43-8)

Magnolol is a bioactive lignin found in the bark of the Houpu magnolia (Magnolia officinalis) which shows antifungal properties.

CFI-401980
(CAS: 1610676-27-1)

CFI-401980, a pyrazolotriazin derivative, has been found to be a TTK inhibitor that could exhibit good antiproliferative activity in some human cancer cell line...

CAS 1264-62-6 Erythromycin Ethylsuccinate

Erythromycin Ethylsuccinate
(CAS: 1264-62-6)

Erythromycin Ethylsuccinate, an oral macrolide antibiotic produced by Streptomyces erythreus, reversibly binds to the 50S ribosome of bacteria, and inhibits pro...

CAS 1641-17-4 Mexenone

Mexenone
(CAS: 1641-17-4)

Mexenone, the derivative of benzophenone, is a sunscreening agent.

CAS 78281-02-4 Hydroxysafflor yellow A

Hydroxysafflor yellow A
(CAS: 78281-02-4)

Hydroxysafflor yellow A is a flavonoid derived. It is extracted from traditional Chinese medicine Carthamus tinctorius L. It possesses anti-tumor activity. It c...

CAS 119793-66-7 Propionyl-L-Carnitine HCl

Propionyl-L-Carnitine HCl
(CAS: 119793-66-7)

The hydrochloride salt form of L-Propionylcarnitine which has been found to be related to mitochondrial metabolism so that could be used in the treatment deteri...

Doxorubicin-SMCC
(CAS: 400647-59-8)

Doxorubicin-SMCC, a derivative of doxorubicin with a SMCC linker, can react with sulfhydryl groups at pH 6.5-7.5 to form a stable thioether bond. Doxorubicin-SM...

CAS 53963-43-2 Ginsenoside F1

Ginsenoside F1
(CAS: 53963-43-2)

Ginsenoside F1, a metabolite of ginsenoside Rg1, which is used as an aldose reductase inhibitor and my exert anti-inflammatory and immunomodulatory activity.

CAS 98-92-0 Nicotinamide

Nicotinamide
(CAS: 98-92-0)

Nicotinamide, a water-soluble vitamin, is an active component of coenzymes NAD and NADP, and also act as an activator of sirtuins.

Reference Reading


1.Rapid quantitative analysis of oxiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry.
Son J1, Lee J, Lee M, Lee E, Lee JH, La S, Kim DH. J Pharm Biomed Anal. 2004 Nov 15;36(3):657-61.
A rapid and accurate reversed-phase liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for the quantitative determination of oxiracetam in human plasma. Oxiracetam, a highly polar compound, was successfully retained by Atlantis dC18 reversed-phase column and detected with triple-quadrupole tandem mass spectrometry. After addition of internal standard (piracetam) to human plasma, plasma was simply precipitated with two volume of acetonitrile, evaporated and dissolved in 0.1% acetic acid. This method for the determination of oxiracetam was accurate and reproducible, with a limit of quantitation of 0.2microg/ml in human plasma. The standard calibration curve for oxiracetam was linear (r(2) = 0.999) over the concentration range 0.2-40.0microg/ml in human plasma. The intra- and inter-day precision over the concentration range of oxiracetam was lower than 8.3% (relative standard deviation, %R.S.D.
2.Calcium entry blockers and oxiracetam have opposite effects on the density of dihydropyridine receptors in rat cerebral cortex.
Dudkin SM1, Polev PV, Soldatov NM. Brain Res. 1990 Aug 20;525(2):319-21.
Ca2+ entry blockers riodipine, D-cis-diltiazem and verapamil, when administered i.p. to rats at a dose of 10 mg/kg, produced two-fold decreases in the density of 1,4-dihydropyridine (DHP) receptors in rat cerebral cortex, as revealed by Scatchard plot analysis of radioligand binding made 24 h after the first injection. Thereafter, the number of DHP binding sites increased up to the initial level on day 4 of the treatment. The nootropic drug oxiracetam, when injected simultaneously with Ca2+ channel blockers at a dose of 10 mg/kg, prevented this transient decrease in DHP receptor density in brain. These results can explain the opposite modulation of memory retention by calcium antagonists and nootropic drugs that has been observed previously.
3.Effects of nootropic drugs in a scopolamine-induced amnesia model in mice.
Verloes R1, Scotto AM, Gobert J, Wülfert E. Psychopharmacology (Berl). 1988;95(2):226-30.
Scopolamine (3 mg/kg IP) given before an acquisition trial, reduced the retention of a one-trial passive avoidance "step through" response in mice. A single administration of cholinergic agonists such as oxotremorine, BM-5, or arecoline, antagonized this amnesic effect of scopolamine. A significant anti-amnesic effect was also found with nootropic drugs such as piracetam and ucb L059, whereas ucb L060 (the enantiomer of ucb L059), oxiracetam and rolziracetam were shown to be ineffective. Moreover, ucb L059, administered twice daily for 3 days, counteracted the amnesic effects of scopolamine completely, whereas ucb L060 was again inactive. The results demonstrate that: (a) this model of impaired cognition by scopolamine is able to discriminate between closely related chemical substances and even stereoisomers; and (b) nootropic drugs, such as ucb L059, are more effective after repeated rather than after acute administration.
4.Glycosides of cistanche improve learning and memory in the rat model of vascular dementia.
Chen J1, Zhou SN, Zhang YM, Feng YL, Wang S. Eur Rev Med Pharmacol Sci. 2015 Apr;19(7):1234-40.
OBJECTIVE: Glycosides of cistanche (GC) is extracted from Xin Jiang Cistanche, which is widely used as a Chinese herb. This study aims to evaluate the effects of GC on vascular dementia (VD).